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Th e report by Kim and colleagues makes an important 
contribution to tailoring endocrine therapy in oestrogen 
receptor-positive breast cancer to women most likely to 
beneﬁ t from it [1]. Oestrogen receptor-positive breast 
cancer is unique among common solid tumours in that it 
has a very long natural history, and it is not possible to 
accurately identify women who can safely be considered 
cured. As a result endocrine therapy is required for at 
least 5 years, and often longer for high-risk patients. Yet 
late recurrences are still common, being about 2.5% per 
year for 20 years with tamoxifen treatment [2] and about 
2% per year with aromatase inhibitors for the 10 years for 
which follow-up data are currently available [3].
Aside from levels of oestrogen and progesterone recep-
tors measured in the primary tumour, little information 
is available to predict response to treatment. Newer 
studies focusing on changes in Ki-67 and other cell cycle 
proteins measured before and after presurgical treatment 
may in the future help to determine which patients are 
responding to a given treatment [4], but current practise 
is to give at least 5  years of endocrine treatment to all 
patients and hope for the best. Early suggestions that 2D6 
polymorphisms, which are involved in the metabolism of 
tamoxifen, might help to predict which patients would 
respond best to this treatment have not been conﬁ rmed 
in more recent large studies [5,6].
Breast density is a well-established risk factor for breast 
cancer in Caucasian women [7], and also in oriental 
women although their average density is higher [8]. 
Breast density responds to hormonal manipulations, 
being increased with hormone replacement therapy [9] 
and importantly reduced with the use of tamoxifen [10]. 
Th e possibility that changes in density might predict drug 
eﬀ ectiveness was hypothesised some time ago [10]. Th is 
prediction was subsequently shown to be the case in the 
preventive setting, where tamoxifen reduced the inci-
dence of breast cancer in high-risk women by about two-
thirds when density was reduced by 10% or more after 12 
to 18 months of treatment but had no eﬀ ect when reduc-
tions were smaller or nonexistent [11]. Th e possibility 
that the same predictive value of density might also be 
true in the adjuvant setting and also for aromatase 
inhibitors was raised in [11], and the current study is the 
ﬁ rst to report such an eﬀ ect.
In their report, Kim and colleagues studied 1,065 
Korean women with oestrogen receptor-positive breast 
cancer, of which 127 (12%) had ductal carcinoma in situ
[1]. All patients received endocrine therapy (tamoxifen or 
an aromatase inhibitor) for a mean duration of 5.1 years. 
Density was assessed in the cranio-caudal view of the 
contralateral breast at baseline and at a mean of 13.1 
months after the start of therapy – blinded to treatment 
allocation and outcome  – using the Cumulus software 
[12]. Sixty per cent of women had baseline density in the 
25 to 50% range. Based on 80 recurrences overall, a clear 
gradient for lower recurrence rates in women with large 
reductions was seen – recurrence rates being more than 
twofold higher in women with no reduction compared 
with those presenting a reduction ≥10%. About one-
quarter of women had changes in each of the four 
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In their report, Kim and colleagues study the ability of 
changes in mammographic density over a period of 
12 to 18 months to predict subsequent recurrence in 
1,065 Korean women with oestrogen receptor-positive 
breast cancer. Based on 80 recurrences, a clear gradient 
for lower recurrence rates was seen among women 
with larger density reductions – with recurrence rates 
being more than twofold higher in women with no 
reduction compared with those presenting a reduction 
≥10%. This extends previous work on predicting the 
eff ectiveness of tamoxifen in individual women from 
the preventive setting to the adjuvant setting, and also 
includes women treated with aromatase inhibitors, 
where a slightly larger eff ect was seen.
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categories of reduction: >10%, 5 to 10%, 0 to 5%, or an 
increase.
Greater density reductions were seen in women receiv-
ing tamoxifen (6.5% mean reduction) than in those 
receiving an aromatase inhibitor (3.1% mean reduction), 
but this appears to be due to their younger age and 
consequently their higher density at entry. Although 
tamoxifen was associated with greater changes in density, 
curiously the predictive value of density appeared to be 
greater with aromatase inhibitors and in postmenopausal 
women. Th e reasons for this increased density are 
unclear and need conﬁ rmation in further studies. 
Mechanisms underlying these ﬁ ndings are also needed, 
and if found could help to identify those women most 
likely to respond to a speciﬁ c treatment before it is 
started, as opposed to the need to wait for the 
approximately 12 to 18  months after treatment has 
commenced to identify density changes in mammograms.
Th is study is the ﬁ rst to show that change in density 
predicts recurrences in the adjuvant setting, and raises 
the possibility of adjusting treatment in individual 
women according to their initial response to treatment in 
terms of density changes. Th is is an important step 
toward personalising treatment for this disease. Further 
work in Caucasian populations – more closely controlled 
for age and speciﬁ c treatment, and integrating other 
factors such as levels of oestrogen and progesterone 
receptors, and baseline Ki-67 levels (and possibly, when 
presurgical endocrine treatment is used, evaluating 
changes in Ki-67 positivity in the tumour)  – oﬀ ers the 
prospect of more accurately choosing a speciﬁ c treatment 
from which an individual woman is most likely to beneﬁ t.
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